litlas
Log inCreate account

Alexander Levitzki

Active 1967–2019

97
Papers
19,919
Citations
82
h-index
96
i10-index

Citations

Citations per year for Alexander Levitzki1965: 2 citations1968: 1 citations1969: 4 citations1970: 15 citations1971: 19 citations1972: 18 citations1973: 22 citations1974: 28 citations1975: 34 citations1976: 51 citations1977: 31 citations1978: 31 citations1979: 37 citations1980: 51 citations1981: 37 citations1982: 46 citations1983: 34 citations1984: 32 citations1985: 19 citations1986: 15 citations1987: 17 citations1988: 31 citations1989: 38 citations1990: 88 citations1991: 105 citations1992: 100 citations1993: 79 citations1994: 123 citations1995: 82 citations1996: 117 citations1997: 120 citations1998: 140 citations1999: 192 citations2000: 201 citations2001: 208 citations2002: 273 citations2003: 294 citations2004: 243 citations2005: 203 citations2006: 227 citations2007: 174 citations2008: 168 citations2009: 124 citations2010: 135 citations2011: 129 citations2012: 135 citations2013: 84 citations2014: 109 citations2015: 75 citations2016: 79 citations2017: 59 citations2018: 51 citations2019: 227 citations2020: 203 citations2021: 144 citations2022: 128 citations2023: 76 citations2024: 91 citations2025: 36 citations2026: 3 citations1966–1967: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,384 citing papers, 41.2% of this breakdownGermany: 380 citing papers, 6.6% of this breakdownChina: 373 citing papers, 6.4% of this breakdownUnited Kingdom: 327 citing papers, 5.7% of this breakdownJapan: 240 citing papers, 4.1% of this breakdownCanada: 179 citing papers, 3.1% of this breakdownItaly: 179 citing papers, 3.1% of this breakdownFrance: 178 citing papers, 3.1% of this breakdownIsrael: 174 citing papers, 3% of this breakdownAustralia: 118 citing papers, 2% of this breakdownSouth Korea: 108 citing papers, 1.9% of this breakdownIndia: 92 citing papers, 1.6% of this breakdown
0%41.2%Other 18.2%

Institutions

Fields

  • Medicine42.7%
  • Biochemistry, Genetics and Molecular Biology41.3%
  • Immunology and Microbiology4.3%
  • Neuroscience3%
  • Chemistry2.6%
  • Computer Science1.4%
  • Other4.7%

Topics

  • Cytokine Signaling Pathways and Interactions5.5%
  • Protein Kinase Regulation and GTPase Signaling3.2%
  • PI3K/AKT/mTOR signaling in cancer3.1%
  • HER2/EGFR in Cancer Research2.6%
  • Receptor Mechanisms and Signaling2%
  • Cancer Mechanisms and Therapy2%
  • Other81.6%

Coauthors

All papers

Open in search
  1. Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells

    Authors: Robyn Catlett-Falcone, Terry H. Landowski, Marc M. Oshiro, James Turkson, Alexander Levitzki, Rocco Savino, Gennaro Ciliberto, Lynn C. Moscinski, José L. Fernández-Luna, Gabriel Núñez, William S. Dalton, Richard Jove - Immunity 1999 cited by 1,651

  2. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling

    Authors: Elsa Sánchez‐López, Efrat Flashner-Abramson, Shabnam Shalapour, Zhenyu Zhong, Koji Taniguchi, Alexander Levitzki, Michael Karin - Oncogene 2015 cited by 161

  3. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells

    Authors: Roy Garcia, Tammy Bowman, Guilian Niu, Hua Yu, Sue Minton, Carlos Muro‐Cacho, Charles E. Cox, Robert E. Falcone, Rita Fairclough, Sarah J. Parsons, Andy Laudano, Aviv Gazit, Alexander Levitzki, Alan J. Kraker, Richard Jove - Oncogene 2001 cited by 764

  4. Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase Inhibitors

    Authors: Pnina Yaish, Aviv Gazit, Chaim Gilon, Alexander Levitzki - Science 1988 cited by 589

  5. ROS, stress‐activated kinases and stress signaling in cancer

    Authors: Moran Benhar, David Engelberg, Alexander Levitzki - EMBO Reports 2002 cited by 596

  6. Cisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor

    Authors: Sabina Winograd‐Katz, Alexander Levitzki - Oncogene 2006 cited by 192

  7. Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance

    Authors: Alexander Levitzki - The Annual Review of Pharmacology and Toxicology 2012 cited by 185

  8. Tyrosine Kinase Inhibition: An Approach to Drug Development

    Authors: Alexander Levitzki, Aviv Gazit - Science 1995 cited by 1,657

  9. Enhanced ROS Production in Oncogenically Transformed Cells Potentiates c-Jun N-Terminal Kinase and p38 Mitogen-Activated Protein Kinase Activation and Sensitization to Genotoxic Stress

    Authors: Moran Benhar, Idan Dalyot, David Engelberg, Alexander Levitzki - Molecular and Cellular Biology 2001 cited by 305

  10. Activation of the Ras/Mitogen-Activated Protein Kinase Pathway by Kinase-Defective Epidermal Growth Factor Receptors Results in Cell Survival but Not Proliferation

    Authors: Francesca Walker, Akiko Kato, L. Jorge Góñez, Margaret L. Hibbs, Normand Pouliot, Alexander Levitzki, Antony W. Burgess - Molecular and Cellular Biology 1998 cited by 119

  11. Information-theoretic analysis of phenotype changes in early stages of carcinogenesis

    Authors: F. Remacle, Nataly Kravchenko‐Balasha, Alexander Levitzki, R. D. Levine - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 cited by 108

  12. Cytidine triphosphate synthetase. Covalent intermediates and mechanisms of action

    Authors: Alexander Levitzki, Daniel E. Koshland - Biochemistry 1971 cited by 124

  13. Ligand-induced dimer-to-tetramer transformation in cytosine triphosphate synthetase

    Authors: Alexander Levitzki, Douglas Koshland - Biochemistry 1972 cited by 110

  14. Tyrosine kinases as targets for cancer therapy

    Authors: Alexander Levitzki - European Journal of Cancer 2002 cited by 102

  15. NEGATIVE COOPERATIVITY IN REGULATORY ENZYMES

    Authors: Alexander Levitzki, Daniel E. Koshland - National Academy of Sciences, Proceedings of the National Academy of Sciences 1969 cited by 388

  16. From Epinephrine to Cyclic AMP

    Authors: Alexander Levitzki - Science 1988 cited by 255

  17. Specific Inhibition of Insulin-Like Growth Factor-1 and Insulin Receptor Tyrosine Kinase Activity and Biological Function by Tyrphostins

    Authors: Marcelina Párrizas, Aviv Gazit, Alexander Levitzki, Efrat Wertheimer, Derek LeRoith - Endocrinology 1997 cited by 206

  18. Protein Kinase Inhibitors as a Therapeutic Modality

    Authors: Alexander Levitzki - Accounts of Chemical Research 2003 cited by 179

  19. Cisplatin-induced activation of the EGF receptor

    Authors: Moran Benhar, David Engelberg, Alexander Levitzki - Oncogene 2002 cited by 144

  20. Therapeutic Destruction of Insulin Receptor Substrates for Cancer Treatment

    Authors: Hadas Reuveni, Efrat Flashner-Abramson, Lilach Steiner, Kirill Makedonski, Renduo Song, Alexei Shir, Meenhard Herlyn, Menashe Bar‐Eli, Alexander Levitzki - Cancer Research 2013 cited by 123

  21. PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases

    Authors: Alexander Levitzki - Cytokine & Growth Factor Reviews 2004 cited by 94

  22. Killing time for cancer cells

    Authors: Shoshana Klein, Frank McCormick, Alexander Levitzki - Nature reviews. Cancer 2005 cited by 91

  23. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors

    Authors: Aviv Gazit, Pnina Yaish, Chaim Gilon, Alexander Levitzki - Journal of Medicinal Chemistry 1989 cited by 605

  24. Transglutaminase is essential in receptor-mediated endocytosis of α2-macroglobulin and polypeptide hormones

    Authors: Peter J. Davies, Dana R. Davies, Alexander Levitzki, Frederick R. Maxfield, Pierre G. Milhaud, Mark C. Willingham, Ira Pastan - Nature 1980 cited by 532